Table 1.

Agents Targeting AR in Clinical Development for Metastatic CRPC

Mechanism of actionDrugPatient populationPhase of developmentClinicaltrials.gov registration number
Rationally designed specific CYP 17 inhibitorsAbiraterone acetateChemotherapy-treatedPhase III: reported at ESMO annual meeting 2010 (19)NCT00638690
Chemotherapy-naïvePhase IIINCT00887198
Orteronel (TAK-700)Chemotherapy treatedPhase IIINCT01193257
Chemotherapy-naïvePhase IIINCT01193244
Novel AR antagonistsMDV-3100Chemotherapy treatedPhase IIINCT00974311
Chemotherapy-naïvePhase IIINCT01212991
AZD3514Phase I-IINCT01162395
ARN-509Phase I-IINCT01171898
Dual CYP 17 inhibitors and AR antagonistTOK-001Phase I-IINCT00959959